SN
SNGX.US Soligenix Inc.
- Market cap
- USD 6.55M
- P/E
- -
- P/B
- 1.08x
- ROE
- -126.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SNGX.US undervalued?
Graham numberThe Graham number of Soligenix Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Soligenix Inc. fundamental analysis
No fundamental analysis for Soligenix Inc. yet.
Soligenix Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulato…
Full company profileSoligenix Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Soligenix Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 10.4M | 5.43M | 5.24M | 3.22M | 1.93M | 33.4K | 250K | 839K | 119K | 0.00 | 0.00 |
| Gross Profit | 2.02M | 1.12M | 644K | -352K | 110K | -695K | -301K | -742K | -119K | 0.00 | -4.39K |
| Operating Income | -5.71M | -7.59M | -9.06M | -10.5M | -18.6M | -13.1M | -14.2M | -7.70M | -9.44M | -11.8M | -8.48M |
| EBITDA | -5.62M | -7.53M | -9.02M | -10.1M | -18.5M | -12.5M | -14.1M | -7.67M | -9.46M | -11.6M | -8.48M |
| Net Income | -3.25M | -7.15M | -8.90M | -9.36M | -17.7M | -12.6M | -13.8M | -6.14M | -8.27M | -11.1M | -7.91M |
| EPS | -217 | -279 | -162 | -116 | -154 | -68 | -77 | -13 | -4.98 | -2.14 | -0.36 |
| Balance Sheet | |||||||||||
| Total Assets | 10.3M | 9.55M | 10.5M | 7.78M | 19.9M | 26.9M | 14.3M | 9.80M | 8.97M | 9.24M | 9.46M |
| Total Liabilities | 2.87M | 3.23M | 4.21M | 6.32M | 16.1M | 16.1M | 16.8M | 7.27M | 4.85M | 3.94M | 3.21M |
| Shareholders' Equity | 7.40M | 6.32M | 6.28M | 1.46M | 3.74M | 10.7M | -2.47M | 2.52M | 4.12M | 5.29M | 6.26M |
| Cash & Short-term Investments | 8.77M | 7.81M | 8.98M | 5.42M | 18.7M | 26.0M | 13.4M | 8.45M | 7.82M | 7.94M | 9.02M |
| Total Debt | - | - | - | 127K | 10.5M | 9.96M | 10.2M | 3.49M | 1.48M | 358K | 274K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.98M | -6.51M | -7.24M | -7.51M | -11.5M | -11.7M | -12.6M | -8.60M | -8.40M | -10.3M | -7.32M |
| Capital Expenditure | 7.16K | 26.3K | 1.93K | 30.2K | 7.15K | 11.8K | 13.1K | 1.00 | 0.00 | 5.88K | 4.00 |
| Free Cash Flow | -4.99M | -6.54M | -7.25M | -7.54M | -11.5M | -11.8M | -12.7M | -8.60M | -8.40M | -10.3M | -7.32M |
| Ratios | |||||||||||
| ROE | -43.9% | -113.1% | -141.7% | -642.1% | -472.7% | -117.1% | - | -243.4% | -200.7% | -209.4% | -126.4% |
| ROA | -31.6% | -74.8% | -84.8% | -120.3% | -88.9% | -46.7% | -96.6% | -62.7% | -92.2% | -120.0% | -83.5% |
| Net Profit Margin | -31.1% | -131.6% | -169.8% | -290.9% | -916.3% | -37,633.0% | -5,519.3% | -731.6% | -6,925.1% | - | - |
| Debt to Equity | - | - | - | 0.09x | 2.81x | 0.93x | - | 1.39x | 0.36x | 0.07x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Soligenix Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 43.00 | 0.00 | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:16 on Jun 6, 2024.
Who owns Soligenix Inc.
- Insiders 9.24%
- Institutions 7.69%
- Public & others 83.07%
- Shares outstanding 23.4M
- Free float 23.4M
Top funds holding SNGX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 75.8K | 0.32% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 14.5K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 8.05K | 0.03% | 0.00% | Sep 2026 |
Top institutions holding SNGX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 210K | 0.90% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 207K | 0.89% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 157K | 0.67% | +655.42% | Jun 2026 |
| Geode Capital Management, LLC | 120K | 0.51% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 81.0K | 0.35% | +38.71% | Jun 2026 |
| Virtu Financial LLC | 60.9K | 0.26% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 53.9K | 0.23% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 44.9K | 0.19% | 0.00% | Sep 2026 |
| Northern Trust Corp | 38.0K | 0.16% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.59K | 0.02% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 3.00K | 0.01% | 0.00% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 1.24K | 0.01% | +1,136.00% | Jun 2026 |
| JPMorgan Chase & Co | 245.00 | 0.00% | -19.67% | Jun 2026 |
| Plante Moran Financial Advisors LP | 209.00 | 0.00% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 5.00 | 0.00% | 0.00% | Jun 2026 |
| Albion Financial Group (Utah) | 3.00 | 0.00% | +50.00% | Jun 2026 |
| SBI Securities Co Ltd | 2.00 | 0.00% | -99.50% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Advisory Services Network, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Soligenix Inc. company profile
- Company name
- Soligenix Inc.
- Ticker
- SNGX.US
- Exchange
- USA Stocks
- Listed since
- Jun 15, 1987
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- 29 Emmons Drive, Princeton, NJ, United States, 08540
- Phone
- 609 538 8200
- Website
- soligenix.com
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Soligenix Inc. management
4- Dr. Christopher J. Schaber Ph.D.Chairman of the Board of Directors, CEO & President · born 1966
- Mr. Jonathan L. Guarino CPA, CGMASenior VP, CFO & Corporate Secretary · born 1973
- Dr. Oreola Donini Ph.D.Senior VP & Chief Scientific Officer · born 1972
- Mr. Adam T. RumageSenior VP of Project Management & Regulatory Affairs